UK – NICE u-turn on Novartis’ migraine drug Aimovig

In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), now recommending the drug's NHS use in a Final Appraisal Document (FAD) on the back of further analysis submitted by the company.

If a final green light follows this decision, people in England and Wales living with four or more migraine days per month, for whom at least three prior preventive drug treatments have failed, will get routine access to this treatment through the NHS.

Aimovig can be self-administered at home every four weeks, and has been shown to be well-tolerated and effective in reducing mean monthly migraine days across the spectrum of migraine, with many patients achieving a 30% or greater reduction…